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Abstract 
Background: Biologic drugs are novel therapeutic agents with demonstrated effectiveness 
in the management of a variety of chronic inflammatory disorders. Unmet needs in the 
treatment of chronic pain have led physicians to utilise a similar approach to patients 
suffering from conditions not characterised by systemic inflammation such as 
osteoarthritis (OA). The aim of this review is to discuss the current knowledge on the use 
of commonly used biologic agents (i.e. anti-tumour necrosis factor alpha (anti-TNF 
alpha) and anti-nerve growth factor (anti-NGF)) for the management of OA. 
Methods: A narrative literature review of studies investigating the use of biologic agents 
for the management of osteoarthritis was conducted. We searched MEDLINE and 
EMBASE for English language publications. A hand-search of reference lists of relevant 
studies was also performed. 
Results: Current evidence does not support TNF-alpha inhibition for the management of 
OA, although a selected subgroup of these patients with a marked inflammatory profile 
may benefit from this therapy. Anti-NGF therapy has been shown to reduce pain and 
improve function compared to placebo and non-steroidal anti-inflammatory drugs in OA 
but concerns remain regarding the safety of such treatment. The discrepant results 
observed in RCTs of biologic agents may be related to heterogeneity, small sample sizes 
and differences in the mode of administration of these drugs. 
Conclusion: Anti-NGF therapy is efficacious for pain in patients with hip and knee OA. 
Despite the fact that current data suggests that anti-cytokine treatments have limited 
efficacy in patients with chronic osteoarthitic pain, larger and better designed studies in 
more selected populations are justified to determine whether such therapeutic approaches 
can improve outcomes in this disabling condition where our medical treatment 
armamentarium is relatively poor. 
 
Keywords: anti-nerve growth factor, anti-tumour necrosis factor alpha, biologic drugs, 
osteoarthritis 
1. Introduction 
Over the last decades advanced progress in biotechnology and pharmaceutical industry 
has been translated into the development of so-called biologic drugs, in particular 
monoclonal antibodies and fusion proteins. Based on their unique properties such as the 
exquisite selectivity with high affinity to the target, biologic molecules constitute a novel 
class of therapeutic agents which have transformed the management of a variety of 
refractory chronic rheumatic, gastrointestinal and cutaneous inflammatory disorders. As 
the routine administration of these regimens is expanding, the potential of fulfilling the 
growing and unmet needs in the treatment of chronic pain have prompted physicians to 
implement similar approaches in patients suffering from conditions not characterised by 
systemic inflammation such as osteoarthritis (OA) [1]. 
OA is probably the most common rheumatic condition affecting humans, characterized 
by chronic joint pain and considerable functional impairment as available 
pharmacological and non-pharmacological treatments have so far been of very limited 
value [2]. Although OA has historically been considered as a non-systemic inflammatory 
condition, a growing body of evidence supports the involvement of pro-inflammatory 
cytokines cascades in the development of cartilage degradation and loss, bone resorption 
and various levels of local, mainly synovial inflammation. Particularly, interleukin-1 (IL-
1) and tumor necrosis factor-alpha (TNF-alpha) which are abundantly produced in 
osteoarthritic joints affect synoviocytes and chondrocytes to synthesize and excrete 
mediators and effectors of bone and synovial tissue turnover [3,4]. This inflammatory 
environment limits the capacity of chondrocytes to self-repair, and the ensuing imbalance 
between loss of cartilage and remodeling results in irreversible cartilage damage and 
matrix degradation (Figure 1). Besides pro-inflammatory properties, TNF-alpha also 
activates central augmentation of pain and interacts with other neuro-inflammatory 
signaling systems and growth factors which are considered as key mediators in 
neuropathic component of osteoarthritic pain [5]. 
 
[Insert Figure 1 here] 
 
Nerve growth factor (NGF) was the first discovered neurotrophic factor and it was 
primarily identified for its role in differentiation and survival of neurones in perinatal and 
early postnatal periods [6]. Recently, much focus has been given to its role in the 
perpetuation of chronic pain [7-9]. NGF is a secreted 13-kDa soluble neurotrophin 
polypeptide [10]. It binds to a non-selective 75 kDa neurotrophin receptor and a high-
affinity NGF-selective tyrosine kinase receptor that are expressed on pain-transducing 
cells called nociceptors. Nociceptors send impulses to the central nervous system, where 
the conscious perception of pain is coordinated and appropriate physiological response is 
initiated. In the context of OA the upregulation of TNF and IL-1 in degenerated joints 
directly induce the expression of NGF in the inflamed tissue leading to increased overall 
activity of peripheral nociceptors and pain perception [11]. NGF also mediates pain 
indirectly by recruiting pro-inflammatory immune cells such as mast cells [12] that 
produce bradykinin, prostaglandin and NGF itself [13]. Intra-articularly, NGF 
upregulates local production of substance P and calcitonin gene-related peptide (CGRP), 
both of which are known to induce joint inflammation and degeneration. Although 
effective blockade of NGF does not directly promote joint tissue regeneration in 
osteoarthritic joints, a reduction in inflammatory processes could allow for self-repair. 
Additionally, anti-NGF reduces both sensitivity to pain and frequency of spontaneous 
pain and this analgesic effect may also improve functionality and overall quality of life in 
patients. 
Experimental and clinical studies confirming the role of anti-NGF in the pain pathway [8-
10] as well as the appreciation that the inflammatory cytokine network contributes to the 
pathogenesis of OA [14] have underpinned the rationale for studies investigating whether 
such novel treatment approaches represent a potential treatment option for OA pain. Most 
of the trials have focused on TNF-alpha inhibitors but there are also reports with other 
anti-cytokine agents investigating the ability of biologic-based therapies to ameliorate 
pain in these highly prevalent and debilitating diseases. This review discusses the current 
knowledge on the use of biologic agents, specifically anti-TNF and anti-NGF for the 
management of osteoarthritis. 
 
2. Methods 
A MEDLINE and EMBASE search up to October 2016 was conducted according to 
published guidance on narrative reviews [15]. A combination of both indexing and free 
text terms was used including osteoarthritis, anti-TNF, anti-NGF, and growth factors. 
Studies were selected for inclusion if evaluating the use of biologic agents for the 
management of osteoarthritis. The search was restricted to articles published in English 
language but also included abstracts submitted in international congresses. A hand search 
of the reference lists of studies meeting the inclusion criteria was also performed to 
identify additional relevant reports. 
3. Results 
3.1. Tumour necrosis factor alpha inhibition 
Given the dramatic effect of TNF-alpha inhibition on pain and structural damage in 
patients with inflammatory arthropathies, rheumatologists have tried to adopt similar 
therapeutic approaches for patients with osteoarthritis, predominantly individuals with 
erosive hand disease. However two double-blind, placebo-controlled trials did not 
demonstrate any superiority of adalimumab compared to placebo in patients with hand 
OA not responding to analgesic or anti-inflammatories in a follow-up period of 6-12 
months [16,17]. In these studies TNF-alpha inhibition did not have any effect on structure 
modification, pain experience, number of painful or swollen joints nor reduced the 
consumption of analgesics in patients with OA; notably adalimumab halted the 
progression of bone erosions in the subgroup of patients with clinically swollen distal 
interphalangeal joints at baseline [16]. More recently a double-blind, placebo-controlled 
trial evaluating the efficacy of subcutaneous etanercept in patients with erosive OA of the 
hands provided promising results regarding the ability of the drug to improve pain and 
modify structural damage, again in patients with more symptomatic, inflammatory 
disease [18]. In the same study, etanercept was effective in improving bone marrow 
lesions predominantly in interphalangeal joints with inflammation at baseline, in a small 
number (n=20) of patients who underwent magnetic resonance imaging [19]. However in 
the whole study population, no difference between etanercept and placebo was observed 
in visual analogue score pain at 24 weeks. Open-label studies have reported similar 
results [20] with the exception of a single-blind study on 10 patients in which 
intraarticular injection of infliximab reduced joint pain and tenderness on palpation when 
individual joints were assessed [21]. Intraarticular administration of the IL-1 receptor 
antagonist, anakinra, failed to provide clinical benefit in patients with knee OA in a 
double-blind placebo RCT [22]. Table 1 summarizes the studies employed anti-cytokine 
biologic drugs in OA individuals.  
Table 1 Studies with TNF-alpha inhibitors in OA patients 
Study Design Patients/ 
Controls 
Molecule Intervention Primary end 
point (months) 
Outcomes 
Chevalier et al 2015 
[17] 
RCT 41/42 ADA 40mg SC/ 2weeks 6/12 (-) VAS 
Chevalier et al 2009 
[22] 
RCT 101/69 ANA 50mg IA/ 150mg 3/12 (-) WOMAC 
Fioravanti et al 2009 
[21] 
Open-
label 
10 INF 0.2 ml IA 12/12 Improvement of 
symptoms 
Kloppenburg et al 
[18] 
RCT 45/45 ETA 50mg SC/ week (24 weeks) 
25mg SC/week (24 weeks) 
12/12 ↓VAS in subgroup 
with swollen joints 
Magnano et al 2007 
[20] 
Open-
Label 
12 ADA 40mg SC/ 2 weeks 3/12 (-) OMERACT 
Verbruggen et al 
2012 [16] 
RCT 30/30 ADA 40mg SC/ 2weeks 12/12 ↓GUSS in subgroup 
with swollen joints 
ADA: adalilumab, ANA: anakinra, ETA: etanercept, GUSS: Ghent University Scoring System, IA: 
intraarticularly, INF: infliximab, OMERCAT: outcome measures in rheumatology, RCT: randomized-
controlled study, SC: subcutaneous, VAS: visual analogue score, WOMAC: Western Ontario and 
McMaster Universities Osteoarthritis Index  
 
3.2. Nerve growth factor inhibition 
The potential use of anti-NGF has been explored in several chronic pain conditions but 
osteoarthritis of the hip and knee being the primary indication for the majority of clinical 
trials (Table 2). 
Unlike the unflattering results from TNF-alpha inhibition, results from clinical trials 
clearly demonstrate that anti-NGF reduces pain and improves functions compared to 
placebo and non-steroidal anti-inflammatory drugs in patients with osteoarthritis of either 
the hip or knee. Naproxen, diclofenac, oxycodone and celecoxib are analgesics with good 
efficacy in osteoarthritis that have often been used as active comparators in anti-NGF 
trials [23,24]. A systematic review of twelve clinical trials showed the unequivocal 
efficacy of anti-NGF compared to placebo and other active comparator in hip and knee 
OA [25]. A noteworthy point in the review was that the standardised effect size in phase 
II trials where study drug was administered on µg/kg basis were greater that Phase III 
trials where fixed doses were administered. However, pharmacokinetic analysis of three 
of the phase III trials included in the review concluded that minimal variability exists 
between fixed versus weight-adjusted dosing, thus indicating that other patient-level 
factors may be responsible for the observed efficacy difference between phase II and III 
trials [26]. 
 
Study Patients in 
treatment 
arm 
Molecule Intervention Control treatment Primary 
end point 
(months) 
Outcomes 
Balanescu et al 2014 
[27] 
453 TAN 3 IV infusion/ 8 
weeks 
Placebo + Diclofenac 4/12 ↓ WOMAC 
↓ PGA 
↔ AE 
Brown et al 2012 [28] 518 TAN 3 IV injection/ 8 
weeks 
Placebo 4/12 ↓ WOMAC 
↓ PGA 
↑ AE 
Brown et al 2013 [29] 466 TAN 3 IV injection/ 8 
weeks 
Placebo 4/12 ↓ WOMAC 
↓ PGA 
↑ AE 
Ekman et al 2011 [30] 624 TAN 2 IV injection/ 8 
weeks 
Naproxen/Placebo 4/12 ↓ WOMAC 
↓ PGA 
↑ AE 
Lane et al 2010 [31] 375 TAN 2 IV injection/ 8 
weeks 
Placebo 4/12 ↓ WOMAC 
↓ PGA 
↑ AE 
Maloney et al 2016 [32] 419 FNB 3 SC injection/ 
12 weeks 
Placebo 4/12 ↓ WOMAC 
↓ PGA 
Mayorga et al 2011 [33] 98 FLN 3 SC injection/ 8 
weeks 
Oxycodone/Placebo 3/12 ↓ WOMAC 
↑TEAE 
Nagashima et al 2011 
[34] 
67 TAN Single IV 
injection 
Placebo 4/12 ↓ Knee pain index 
↓WOMAC 
↔TEAE 
Sanga et al 2013 [35] 356 FLN 3 SC injection/4 
weeks; 2 SC 
injection/8 
weeks 
Placebo 4/12 ↓ OAPI 
↓ WOMAC 
↔TEAE 
Schnitzer et al 2015 [36] 2,161 TAN 2 IV injection/ 8 
weeks 
Naproxen/Celecoxib 4/12 ↓WOMAC 
↑OMERACT-
OARSI 
↑AE 
Spierings et al 2013 [37] 472 TAN 2 IV infusion/ 8 
weeks 
Oxycodone/Placebo 4/12 ↓ WOMAC 
↓ PGA 
↑ AE 
Tiseo et al 2014 [38] 160 FNB 2 IV infusion/ 8 
weeks 
Placebo 24/12 ↔ TEAE 
↓ WOMAC 
↑PGIC 
Table 2 Phase II and III clinical trials of anti-NGF agents for osteoarthritis 
AE: adverse event; FLN: fulranumab, FNB: fasinumab, IV: intravenous, OAPI: osteoarthritis pain 
intensity, OMERACT-OARSI: Outcome Measures in Rheumatology-Osteoarthritis Research Society 
International, PGA: patient's global assessment, PGIC: Patient Global Impression of Change, SC: 
subcutaneous, TAN: tanezumab, TEAE: treatment-emergent adverse event, WOMAC: Western Ontario 
and McMaster Universities Osteoarthritis Index 
 
4. Discussion 
Over the last decades advances in the understanding of OA pathophysiology have 
illustrated that inflammatory cytokine network is substantially involved in initiation and 
propagation of structural bone and cartilage tissues changes. Therefore the use of biologic 
molecules targeting specific inflammatory and pain signaling pathways to ameliorate 
chronic osteoarthritic pain is based on a sound rationale.  
Clinical research results however did not meet the expectations as three double blind 
placebo controlled studies conducted in patients with erosive inflammatory arthritis of the 
hands failed to demonstrate superiority of TNF-alpha inhibitors in terms of pain scores 
and functional improvement [16,18,20]. On the other hand the findings of these trials 
indicate that specific subsets of OA individuals with erosive hand disease may benefit 
from biologic drugs. Particularly the subset of patients with a pronounced inflammatory 
element contributing to the symptoms appear to respond better and more importantly may 
represent the best target population for future trials. In that respect recent reports from 
ultrasound based studies suggesting that ultrasound determined synovitis in the small 
joints of the hands is an independent predictor of the development of joint erosions at 2 
[39] and 4 years [40] lend more support to the concept that enhanced residual 
inflammatory activity may represent a potential target for research in this particular 
subgroup of patients. 
Of course the launch of future studies investigating the effect of TNF-alpha inhibition on 
OA should be considered against the background of limitations particularly in view of 
high costs. The limited effect of biologic drugs demonstrated to-date raises doubts for the 
cost-effectiveness of trials in this field, however the high economic burden and the social 
consequences associated with OA [41] as well as the failure of other treatment 
approaches – for example a recently presented negative double blind placebo-controlled 
hydroxychloroquine trial [42] - emphasize the need for better therapeutic strategies in 
OA, still a neglected disease [43]. Current financial constraints mandate the 
implementation of value-based medicine and in this regard the identification of patients 
more likely to benefit from biologic drugs using ultrasound as a screening tool for future 
trials and the potential introduction of biosimilars [44] may reduce the costs of biotherapy 
given that RCTs with hard end-points may confirm the effectiveness of these regimens in 
OA of the hands. 
Whereas NGF blockade has been quite effective in patients with OA of the knee and the 
hip, safety considerations forced US Food and Drug Administration (FDA) to suspend 
trials on anti-NGF mAb in 2010 due to reported cases of osteonecrosis that led to total 
joint replacement, and severe peripheral neuropathy in trials. The adverse event profile in 
other anti-NGF trials for osteoarthritis, which suggested class effect, was particularly 
crucial in tipping the FDA’s decision to suspend the trials except for patients with 
terminal cancer [45]. Although the FDA decision has been reversed in 2012, the concern 
over adverse events remains. No clear association between anti-NGF and osteonecrosis 
has been demonstrated as rapidly progressive joint degeneration can be considered as a 
natural course of OA in some patients and osteonecrosis can also co-exist with OA at 
some stage [46]. Osteonecrosis has not been observed in trials assessing the effect in 
other chronic conditions, demonstrating the importance of patient characteristics [47]. 
Another proposed indirect reason for the relatively higher incidence of joint destruction 
in patients receiving anti-NGF is based on the assumption that pain reduction encourages 
increased joint activity and overloading [45,48]. A recent animal model seems to support 
this idea [49]. While these are plausible reasons, OA treatments should aim to reduce 
pain and, to a reasonable extent, improve function. Successful treatments may result in 
patients resuming normal activity which may inadvertently lead to additional pressure on 
the joint. As with any other drug, the benefit-risk ratio of treatment with anti-NGF for 
OA should therefore be carefully considered by clinicians and patients. 
Although data is inconsistent, it appears that biologic molecules are not effective in 
improving pain and outcomes in patients with severe OA. Targeting of other cytokine 
signaling pathways such as IL-1 – there is currently a planned trial [50] - IL-6 and IL-17 
should be investigated. The latter may play in role in the activation of chondrocytes and 
production of inflammatory mediators but no clinical data is available to-date [14]. 
Biologic drugs blocking the inflammatory properties of IL-17 are successfully used in the 
spondyloarthropathies [51] but their effectiveness in OA has not been explored. The 
delineation of complex mechanisms of osteoarthritic pain and the recognition of a 
neuropathic component with central pain perception have shed more light in our 
understanding of chronic pain in this condition [52]. Novel therapies blocking central 
pain sensitization pathways are under investigation and may open new avenues in 
optimization of pain management in OA. 
 
5. Conclusion 
Optimal management of chronic pain and disability in conditions such as osteoarthritis in 
which locally produced inflammatory cytokines and central pain perception interfere with 
each other remains an unmet need in the modern treatment era. The discovery and 
development of biologic molecules as well as the ultimate utilization of cytokine-targeted 
therapies for analgesia in these conditions is very much in the ascendance. RCTs have not 
met the initial expectations based on case reports regarding the ability of biologics to 
replenish the supply of novel therapies in pain control and transform the standard of care 
in the same way that such regimens have achieved for inflammatory arthropathies. 
Effective inhibition of NGF pathway has proved efficacy in alleviating pain and 
improving functional status particularly in patients with large joint involvement but 
concerns about the safety have delayed translation and validation of these findings in the 
daily routine clinical setting. The better understanding of the complex mechanisms, the 
cytokine networks and the mediators contributing to the clinical presentation and long 
term outcomes in these conditions have shifted the treatment paradigm towards the whole 
system responsible for the development of chronic pain including neuropathic type of 
pain, as therapies targeting one single cytokine or component of pain appear to have 
limited effect. Inter-individual variations in pain perception and persistence should also 
be taken into consideration in the design and the interpretation of results of future trials. 
Larger and better designed studies particularly in respect of, doses ranges, treatment 
administration intervals and sub-group definition of disease, may be more likely to 
identify a future clinical role of biologic drugs in these conditions taking always into 
account the cost-effectiveness of such therapeutic strategies. 
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 Figure 1 Mechanisms of pain and biologic treatment targets in osteoarthritic joint 
Activated macrophage synoviocytes and chondrocytes produce pro-inflammatory mediators 
which in turn activate peripheral nociceptors that innervate the synovial capsule, periosteum and 
subchondral bone contributing to peripheral sensitization and hyperexcitability of nociceptive 
neurons in the central nervous system. Neurotrophic factors, predominantly NGF further 
exacerbate joint destruction process and inflammation by upregulating neuropeptides such as 
calcitonin gene-related peptide and substance P which promote mechanical sensitization of the 
joint. Blockade of these pathways may diminish the degree of immune responses with direct and 
indirect beneficial effects on joint degeneration and pain perception. Cytokine-targeted pathways 
reduce the synthesis and release of intra-articular mediators while inhibition of NGF-mediated 
pathways may result in the reduction of synovial inflammation and alleviation of pain symptoms. 
IL-1: interleukin-1, NGF: nerve growth factor, TNF-alpha: tumor necrosis factor-alpha. 
 
 
